.jetcityimage/iStock Content via Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its own top biopharma pick for 2025 and measured one more 9 labels in the space as obese. The investment financial institution stated in a keep in mind that it continues to believe “diabesity is actually readied to become.